{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T00:01:12Z","timestamp":1790380872059,"version":"4.1.0"},"reference-count":38,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2008,12,10]],"date-time":"2008-12-10T00:00:00Z","timestamp":1228867200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2009,2]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Relapsed acute lymphoblastic leukaemia (ALL) is the most common cause for a fatal outcome in paediatric oncology. Although initial ALL cure rates have improved up to 80%, the prognosis of recurrent ALL remains dismal with event\u2010free\u2010survival (EFS) rates about 35%. In order to analyse a population\u2010based cohort with uniform treatment of initial disease, we examined the outcome of children suffering from relapsed ALL in Austria for the past 20\u2003years and the validity of the currently used prognostic factors (e.g. time to and site of relapse, immunophenotype). Furthermore, we compared survival rates after chemotherapy alone with those after allogeneic stem cell transplantation (SCT). All 896 patients who suffered from ALL in Austria between 1981 and 1999 were registered in a prospectively designed database and treated according to trials ALL\u2010Berlin\u2010Frankfurt\u2010M\u00fcnster (BFM)\u2010Austria (A) 81, ALL\u2010A 84 and ALL\u2010BFM\u2010A 86, 90 and 95. Of these, 203 (23%) suffered from recurrent disease. One\u2010hundred\u2010and\u2010seventy\u2010two patients (85%) achieved second complete remission. The probability of 10\u2010year EFS for the total group was 34\u2003\u00b1\u20033%. Clinical prognostic markers that independently influenced survival were time to relapse, site of relapse and the immunophenotype. Additionally, a Cox regression model demonstrated that allogeneic SCT after first relapse was associated with a superior EFS compared with chemo\/radiotherapy only (hazard ratio\u2003=\u20030\u00b7254; <jats:italic>P<\/jats:italic>\u2003=\u20030\u00b70017).<\/jats:p>","DOI":"10.1111\/j.1365-2141.2008.07499.x","type":"journal-article","created":{"date-parts":[[2008,12,10]],"date-time":"2008-12-10T15:30:58Z","timestamp":1228923058000},"page":"559-570","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":69,"title":["Long\u2010term outcome of initially homogenously treated and relapsed childhood acute lymphoblastic leukaemia in Austria \u2013 A population\u2010based report of the Austrian Berlin\u2010Frankfurt\u2010M\u00fcnster (BFM) Study Group"],"prefix":"10.1111","volume":"144","author":[{"given":"Bettina","family":"Reism\u00fcller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andishe","family":"Attarbaschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael N.","family":"Dworzak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"P\u00f6tschger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Urban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franz\u2010Martin","family":"Fink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Meister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Schmitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Dieckmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fcnter","family":"Henze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oskar A.","family":"Haas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helmut","family":"Gadner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Mann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the Austrian Berlin\u2010Frankfurt\u2010M\u00fcnster (BFM) Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,1,21]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200004063421402"},{"key":"e_1_2_7_3_1","first-page":"148","article-title":"Treatment results of childhood acute lymphoblastic leukemia in Austria \u2013 a report of 20 years\u2019 experience","volume":"114","author":"Attarbaschi A.","year":"2002","journal-title":"Wiener Klinische Wochenschrift"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403471"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404507"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199411103311902"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19890515)63:10<2066::AID-CNCR2820631032>3.0.CO;2-I"},{"key":"e_1_2_7_8_1","first-page":"1783","article-title":"Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL)","volume":"9","author":"Bene M.C.","year":"1995","journal-title":"Leukemia"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V101.10.3835"},{"key":"e_1_2_7_10_1","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1182\/blood.V90.2.571","article-title":"Incidence and clinical relevance of TEL\/AML1 fusion genes in children with acute lymphoblastic leukemia enrolled in the German and Italian multicenter therapy trials. Associazione Italiana Ematologia Oncologia Pediatirca and the Berlin\u2010Frankfurt\u2010Munster Study Group","volume":"90","author":"Borkhardt A.","year":"1997","journal-title":"Blood"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(20000301)88:5<1166::AID-CNCR29>3.0.CO;2-W"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04584.x"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V78.10.2780.2780"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.01.1031"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6601130"},{"key":"e_1_2_7_16_1","first-page":"140","article-title":"Cooperative studies in the treatment of acute lymphoblastic leukemia in children in Austria \u2010 report of 10 years\u2019 experience","volume":"97","author":"Gadner H.","year":"1985","journal-title":"Wiener Klinische Wochenschrift"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19980401)82:7<1387::AID-CNCR24>3.0.CO;2-1"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.5856"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-0734.2002.00069.x"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008381801403"},{"key":"e_1_2_7_21_1","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1182\/blood.V83.8.2274.2274","article-title":"Cytogenetic features of infants less than 12 months of age at diagnosis of acute lymphoblastic leukemia: impact of the 11q23 breakpoint on outcome: a report of the Childrens Cancer Group","volume":"83","author":"Heerema N.A.","year":"1994","journal-title":"Blood"},{"key":"e_1_2_7_22_1","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1182\/blood.V78.5.1166.1166","article-title":"Six\u2010year experience with a comprehensive approach to the treatment of recurrent childhood acute lymphoblastic leukemia (ALL\u2010REZ BFM 85). A relapse study of the BFM group","volume":"78","author":"Henze G.","year":"1991","journal-title":"Blood"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.8554"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1703271"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2000.01891.x"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1097\/00062752-200207000-00013"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08782-2"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05572.x"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401977"},{"key":"e_1_2_7_31_1","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1182\/blood.V91.5.1716.1716_1716_1722","article-title":"TEL\u2010AML1 fusion transcript in relapsed childhood acute lymphoblastic leukemia","volume":"91","author":"Seeger K.","year":"1998","journal-title":"Blood"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.13.3188"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1701802"},{"key":"e_1_2_7_34_1","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1200\/JCO.1995.13.2.352","article-title":"Treatment of childhood acute lymphoblastic leukemia in second remission with allogeneic bone marrow transplantation and chemotherapy: ten\u2010year experience of the Italian Pediatric Hematology Oncology Association","volume":"13","author":"Uderzo C.","year":"1995","journal-title":"Journal of Clinical Oncology"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2004.04925.x"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1998.00676.x"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1535-6108(02)00032-6"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19860715)58:2 <598::AID-CNCR2820581332>3.0.CO;2-C"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402749"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2141.2008.07499.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2141.2008.07499.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T22:34:35Z","timestamp":1695940475000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2141.2008.07499.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1,21]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009,2]]}},"alternative-id":["10.1111\/j.1365-2141.2008.07499.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2141.2008.07499.x","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,1,21]]},"assertion":[{"value":"2009-01-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}